$299 Million is the total value of Altium Capital Management LP's 118 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLU | BELLUS HEALTH INC NEW | $9,976,000 | -14.5% | 1,450,006 | 0.0% | 3.34% | +3.7% | |
| KDNY | CHINOOK THERAPEUTICS INC | $8,916,000 | +0.3% | 545,000 | 0.0% | 2.98% | +21.7% | |
| ADMA | ADMA BIOLOGICS INC | $6,039,000 | +29.8% | 3,300,000 | 0.0% | 2.02% | +57.5% | |
| RLMD | RELMADA THERAPEUTICS INC | $5,560,000 | +19.8% | 206,000 | 0.0% | 1.86% | +45.4% | |
| CBAY | CYMABAY THERAPEUTICS INC | $5,443,000 | -8.0% | 1,750,000 | 0.0% | 1.82% | +11.7% | |
| MBTC | NOCTURNE ACQUISITION CORPordinary shares | $5,040,000 | +0.8% | 500,000 | 0.0% | 1.69% | +22.3% | |
| QGEN | QIAGEN NV | $4,557,000 | -11.8% | 93,000 | 0.0% | 1.52% | +7.0% | |
| XTNT | XTANT MED HLDGS INC | $4,247,000 | +21.4% | 6,246,291 | 0.0% | 1.42% | +47.4% | |
| EUCR | EUCRATES BIOMEDICAL ACQU COR | $3,936,000 | +0.8% | 400,000 | 0.0% | 1.32% | +22.4% | |
| GOEDWS | 1847 GOEDEKER INC*w exp 06/02/202 | $3,778,000 | -48.8% | 6,103,824 | 0.0% | 1.26% | -37.9% | |
| OCUL | OCULAR THERAPEUTIX INC | $3,440,000 | -29.0% | 695,000 | 0.0% | 1.15% | -13.8% | |
| KRMD | REPRO MED SYS INC | $2,847,000 | -4.7% | 995,500 | 0.0% | 0.95% | +15.7% | |
| TMPM | TURMERIC ACQUISITION CORPcl a | $2,502,000 | +0.3% | 254,000 | 0.0% | 0.84% | +21.7% | |
| MORF | MORPHIC HLDG INC | $2,409,000 | -15.3% | 60,000 | 0.0% | 0.81% | +2.8% | |
| SRSA | SARISSA CAPITAL ACQUISITN COcl a | $2,228,000 | +1.1% | 225,000 | 0.0% | 0.75% | +22.9% | |
| TG VENTURE ACQUISITION CORPunit 08/15/2028 | $2,004,000 | -2.2% | 200,000 | 0.0% | 0.67% | +18.8% | ||
| GIGINTERNATIONAL1 INC | $2,000,000 | +0.7% | 200,000 | 0.0% | 0.67% | +22.1% | ||
| LAKESHORE ACQUISITION I CORPordinary shares | $1,982,000 | +0.5% | 200,000 | 0.0% | 0.66% | +21.9% | ||
| CHAVANT CAPITAL ACQUISITN COordinary shares | $1,982,000 | +0.7% | 200,000 | 0.0% | 0.66% | +22.1% | ||
| JYAC | JIYA ACQUISITION CORP | $1,966,000 | +0.6% | 200,000 | 0.0% | 0.66% | +22.1% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $1,871,000 | +18.3% | 54,000 | 0.0% | 0.63% | +43.6% | |
| CTMX | CYTOMX THERAPEUTICS INC | $1,772,000 | -38.3% | 663,800 | 0.0% | 0.59% | -25.1% | |
| RENOVACOR INC | $1,649,000 | -44.9% | 388,845 | 0.0% | 0.55% | -33.2% | ||
| DIGITAL HEALTH ACQUISITION Cunit 11/02/2026 | $1,515,000 | -1.4% | 150,000 | 0.0% | 0.51% | +19.6% | ||
| TWND | TAILWIND ACQUISITION CORP | $1,271,000 | +0.6% | 128,414 | 0.0% | 0.42% | +21.8% | |
| FATBW | FAT BRANDS INC*w exp 07/16/202 | $1,022,000 | -33.3% | 227,000 | 0.0% | 0.34% | -19.1% | |
| INDUSTRIAL HUMAN CAPITAL INC | $1,002,000 | +1.0% | 100,000 | 0.0% | 0.34% | +22.3% | ||
| BLSA | BCLS ACQUISITION CORP | $987,000 | +0.7% | 100,000 | 0.0% | 0.33% | +22.2% | |
| OMEG | OMEGA ALPHA SPACcl a | $982,000 | +0.5% | 100,000 | 0.0% | 0.33% | +22.3% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $980,000 | -1.2% | 100,000 | 0.0% | 0.33% | +19.7% | |
| ACHIEVE LIFE SCIENCES INC | $924,000 | -2.6% | 122,000 | 0.0% | 0.31% | +17.9% | ||
| COLISEUM ACQUISITION CORP | $825,000 | -0.1% | 85,000 | 0.0% | 0.28% | +21.1% | ||
| VRCA | VERRICA PHARMACEUTICALS INC | $794,000 | -11.5% | 97,887 | 0.0% | 0.27% | +7.7% | |
| DOUBLEDOWN INTERACTIVE CO LTads | $722,000 | -23.5% | 60,876 | 0.0% | 0.24% | -6.9% | ||
| CLBR | COLOMBIER ACQUISITION CORPcl a | $484,000 | +0.4% | 50,000 | 0.0% | 0.16% | +21.8% | |
| RENOVACOR INC*w exp 99/99/999 | $249,000 | -40.3% | 731,561 | 0.0% | 0.08% | -27.8% | ||
| HARBOR CUSTOM DEVELOPMENT IN*w exp 10/04/202 | $240,000 | -52.1% | 650,000 | 0.0% | 0.08% | -42.0% | ||
| SURGEPAYS INC*w exp 10/22/202 | $223,000 | +38.5% | 250,000 | 0.0% | 0.08% | +70.5% | ||
| HCDIW | HARBOR CUSTOM DEVELOPMENT IN*w exp 05/09/202 | $171,000 | -26.9% | 600,000 | 0.0% | 0.06% | -12.3% | |
| IMTXW | IMMATICS N.V*w exp 07/01/202 | $171,000 | -60.0% | 97,467 | 0.0% | 0.06% | -51.7% | |
| PEPPERLIME HEALTH ACQUSTN CO*w exp 10/01/202 | $152,000 | -7.9% | 367,500 | 0.0% | 0.05% | +13.3% | ||
| CINGULATE INC*w exp 12/03/202 | $108,000 | -43.8% | 270,000 | 0.0% | 0.04% | -32.1% | ||
| MBTCR | NOCTURNE ACQUISITION CORPright 12/26/2025 | $105,000 | -47.5% | 500,000 | 0.0% | 0.04% | -36.4% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $99,000 | -2.0% | 10,000 | 0.0% | 0.03% | +17.9% | |
| NEXGEL INC*w exp 12/01/202 | $88,000 | -51.6% | 225,000 | 0.0% | 0.03% | -42.0% | ||
| NLSPW | NLS PHARMACEUTICS LTD*w exp 09/25/202 | $76,000 | -47.9% | 200,000 | 0.0% | 0.02% | -37.5% | |
| LAKESHORE ACQUISITION I CORP*w exp 07/15/202 | $53,000 | -54.3% | 150,000 | 0.0% | 0.02% | -43.8% | ||
| CHAVANT CAPITAL ACQUISITN CO*w exp 99/99/999 | $30,000 | -59.5% | 150,000 | 0.0% | 0.01% | -50.0% | ||
| SRSAW | SARISSA CAPITAL ACQUISITN CO*w exp 10/23/202 | $27,000 | -62.0% | 75,000 | 0.0% | 0.01% | -55.0% | |
| EUCRW | EUCRATES BIOMEDICAL ACQU COR*w exp 10/23/202 | $25,000 | -67.5% | 133,333 | 0.0% | 0.01% | -61.9% | |
| TMPMW | TURMERIC ACQUISITION CORP*w exp 10/08/202 | $24,000 | -52.9% | 84,666 | 0.0% | 0.01% | -42.9% | |
| SURROZEN INC*w exp 08/01/203 | $21,000 | -77.9% | 82,233 | 0.0% | 0.01% | -73.1% | ||
| GIGINTERNATIONAL1 INC*w exp 04/19/202 | $18,000 | -37.9% | 50,000 | 0.0% | 0.01% | -25.0% | ||
| INDUSTRIAL HUMAN CAPITAL INC*w exp 11/27/202 | $18,000 | -52.6% | 100,000 | 0.0% | 0.01% | -40.0% | ||
| COLISEUM ACQUISITION CORP*w exp 08/22/202 | $10,000 | -56.5% | 28,333 | 0.0% | 0.00% | -50.0% | ||
| CLBRWS | COLOMBIER ACQUISITION CORP*w exp 99/99/999 | $5,000 | -44.4% | 16,666 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
| XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
| IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
| MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
| HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
| CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
| CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
| POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
| Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
| HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
| Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
| NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| 1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
| BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
| BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.